



Press Release

Jul 7, 2022

Eli Lilly Japan K.K.
Mitsubishi Tanabe Pharma Corporation

Eli Lilly Japan and Mitsubishi Tanabe Pharma Corporation signed a sales collaboration agreement in Japan for GIP/GLP-1 receptor agonist “Tirzepatide”

Eli Lilly Japan K.K. (Head Office: Kobe, Japan, Representative Director and President: Simone Thomsen, hereinafter called “Eli Lilly Japan”) and Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan, Representative Director: Hiroaki Ueno, hereinafter called “MTPC”) announced that the two companies signed a sales collaboration agreement in Japan for Tirzepatide, which is under development by Eli Lilly Japan.

Tirzepatide (injection) is a novel once-weekly GIP (glucose-dependent insulintropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist that integrates the actions of the GIP and GLP-1 incretins into a single molecule, representing a new class of medicines being developed for the treatment of type 2 diabetes by Eli Lilly Japan. In the U.S., Tirzepatide was already FDA-approved on May 13 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Based on the agreement, after Eli Lilly Japan retains a manufacturing/marketing license for Tirzepatide, MTPC will take responsibility for sales/distribution of the medicine. Eli Lilly Japan and MTPC will conduct activities to provide healthcare professionals with information regarding Tirzepatide.

Eli Lilly Japan continues to provide a broad product portfolio and unique services to meet the various needs of people living with diabetes. MTPC has developed several antidiabetic drugs and is engaged in information provision activities in the diabetes field in order to creating hope to all facing illness. The two companies entered into this alliance because we believe that by working together, we can provide appropriate information to a wide range of medical institutions and deliver Tirzepatide promptly to a greater number of patients who need it.

Eli Lilly Japan and MTPC will closely work together through the sales collaboration for Tirzepatide, which is expected to be a new option for the treatment of type 2 diabetes, and make further contributions to the treatment of diabetes.

About Tirzepatide

Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. GIP is a hormone that may complement the effects of GLP-1. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with a GLP-1 receptor agonist, may result in greater effects on glucose and body weight. Tirzepatide is in phase 3 development for blood glucose management in adults with type 2 diabetes, for chronic weight management and heart failure with preserved ejection fraction (HFpEF). It is also being studied as a potential treatment for non-alcoholic steatohepatitis (NASH).

About Eli Lilly Japan

Eli Lilly Japan K.K. is a subsidiary of US-based Eli Lilly and Company. It contributes to medical treatment in Japan through the development, manufacture, import and sale of innovative pharmaceutical products that enable people to live longer, healthier, and more fulfilling lives, focusing on the therapeutic areas such as cancer, diabetes, musculoskeletal diseases, central nervous system diseases, autoimmune diseases, growth disorder, and pain. For more information, visit <http://www.lilly.co.jp>

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of the Mitsubishi Chemical Group, is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. The Mitsubishi Chemical Group has positioned Health Care as one of its strategic focus in its management policy, "Forging the future". MTPC set the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on R&D in the areas of central nervous system and immunoinflammation and vaccines for global market, and it is also focusing on the areas of diabetes and kidney disease in Japan. For more information, go to <https://www.mt-pharma.co.jp/e/>